Assignee
ACTINIUM PHARMACEUTICALS INC
US·19 granted patents·40 pending applications·34 citations·filing 2001–2025
Top patents by PatentIndex Score
59 records- 0190US11844799B2Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeuticACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Dec 19, 2023·2 cites·2 claims
- 0289US9790573B2Method for purification of 225AC from irradiated 226RA-targetsACTINIUM PHARMACEUTICALS INC·Filed 2016·Granted Oct 17, 2017·10 cites·22 claims
- 0386US11364235B2Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeuticACTINIUM PHARMACEUTICALS INC·Filed 2018·Granted Jun 21, 2022·4 cites·18 claims
- 0482US12133849B2Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeuticACTINIUM PHARMACEUTICALS INC·Filed 2023·Granted Nov 5, 2024·0 cites·7 claims
- 0581US2025017919A1Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeuticACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0678US9534277B1Method for purification of 225AC from irradiated 226RA-targetsACTINIUM PHARMACEUTICALS INC·Filed 2014·Granted Jan 3, 2017·4 cites·22 claims
- 0777US11292835B2Low dose antibody-based methods for treating hematologic malignanciesACTINIUM PHARMACEUTICALS INC·Filed 2017·Granted Apr 5, 2022·1 cites·6 claims
- 0877US8349391B2Radium target and method for producing itACTINIUM PHARMACEUTICALS INC·Filed 2006·Granted Jan 8, 2013·9 cites·44 claims
- 0976US11975081B2Bifunctional chelators and conjugatesACTINIUM PHARMACEUTICALS INC·Filed 2023·Granted May 7, 2024·0 cites·26 claims
- 1076US11964948B2Bifunctional chelators and conjugatesACTINIUM PHARMACEUTICALS INC·Filed 2023·Granted Apr 23, 2024·0 cites·23 claims
- 1175US11241512B2Stabilized radio-labeled anti-CD45 immunoglobulin compositionsACTINIUM PHARMACEUTICALS INC·Filed 2019·Granted Feb 8, 2022·0 cites·8 claims
- 1275US2022118122A1Stabilized radiolabeled anti-cd45 immunoglobulin compositionsACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1372US2024408250A1Methods for treatment of patients with myelodysplastic syndromesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1471US11912780B2Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapiesACTINIUM PHARMACEUTICALS INC·Filed 2018·Granted Feb 27, 2024·1 cites·25 claims
- 1571US7374936B2Method and means for site directed therapyACTINIUM PHARMACEUTICALS INC·Filed 2001·Granted May 20, 2008·3 cites·9 claims
- 1671US2024254092A1Bifunctional chelators and conjugatesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1768US12410249B2Low dose antibody-based methods for treating hematologic malignanciesACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Sep 9, 2025·0 cites·13 claims
- 1868US11981741B2Humanized anti-CD45 antibodiesACTINIUM PHARMACEUTICALS INC·Filed 2023·Granted May 14, 2024·0 cites·11 claims
- 1968US2008279772A1Methods for detecting pathological sitesACTINIUM PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2067US2025121105A1Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugatesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2166US2026053963A1Radioconjugates targeting cd33 in the treatment of breast cancerACTINIUM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2265US12491274B2Radioconjugates targeting CD33 in the treatment of sarcomasACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Dec 9, 2025·0 cites·2 claims
- 2365US2009191122A1Method for purification of 225ac from irradiated 226ra-targetsACTINIUM PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 2464US2024158528A1Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapiesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2563US2024301081A1Humanized anti-cd45 antibodiesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2661US12083192B2Methods for treatment of patients with myelodysplastic syndromesACTINIUM PHARMACEUTICALS INC·Filed 2018·Granted Sep 10, 2024·0 cites·18 claims
- 2759US2013266475A1Method for purification of 225ac from irradiated 226ra-targetsACTINIUM PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2858US2025205375A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2957US12539340B2Radioconjugates targeting CD33 in the treatment of cancersACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Feb 3, 2026·0 cites·18 claims
- 3056US12447218B1Radioconjugates directed to MHC-complexed antigens in cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Oct 21, 2025·0 cites·4 claims
- 3156US2025073274A1Methods for treating cd33-positive hematological malignanciesACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3256US2025281654A1Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agentsACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3355US2023416348A1Calreticulin nanobodiesACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3455US2025289875A1Grp78 nanobodiesACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3554US2026000795A1Her3 nanobodiesACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3654US2023248855A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3753US2022251239A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3853US2022288244A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3952US2022211886A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4051US2024299600A1Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225ACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4151US2024390532A1Radioimmunoconjugates targeting grp78 for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4251US2024216554A1Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4350US12551584B1Lewis Y radioimmunotherapy for the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2021·Granted Feb 17, 2026·0 cites·7 claims
- 4450US2025339571A1Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4549US2024226345A1Radioimmunoconjugates targeting calreticulin for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4649US2022143228A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4749US2022072167A1Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody RadioconjugatesACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4848US2020338219A1Molecules and their derivatives directed aganist cd45ACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4948US2024197931A1Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cellsACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 5048US2022211885A1Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseasesACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ACTINIUM PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →